Skip to main content
. 2021 Jul 23;9(1):e002257. doi: 10.1136/bmjdrc-2021-002257

Table 1.

Characteristics of the 304 study participants

Potential predictor Outcome Missing values n (%)
Age (years) 64.6±10.5
Males 220 (72.4)
Body mass index (kg/m2) 29.8±5.3
Caucasian 283 (93.1)
Type of diabetes 4 (1.3)
 Type 1 66 (21.7)
 Type 2 234 (77.0)
 Years of diabetes 20±14 3 (1.0)
 HbA1c (%) 7.7±3.6 65 (21.4)
 Retinopathy 151 (49.7) 2 (0.7)
 Nephropathy 60 (19.7) 1 (0.3)
 Dialysis 4 (1.3)
 Smoking or history of smoking 169 (55.6)
 Consumption of alcohol 199 (65.5)
 Walking aid 89 (29.3)
 Living alone 105 (34.5)
Level of education 2 (0.7)
 Low 117 (38.5)
 Medium 96 (31.6)
 High 89 (29.3)
 Employed 75 (24.7)
 Custom-made footwear 205 (67.4) 2 (0.7)
 Walking barefoot at home 113 (37.2)
 Adherence to self-care 4.7±1.4
 At-home foot temperature monitoring 151 (49.7)
Care center
 University medical center 88 (28.9)
 Community hospital 134 (44.1)
 Podiatry practice 82 (27.0)
Peripheral neuropathy
 Mild 28 (9.2)
 Severe 276 (90.8)
Peripheral artery disease
 Grade 1 197 (64.8)
 Grade 2 107 (35.2)
Foot deformity
 Absent 17 (5.6)
 Mild 58 (19.1)
 Moderate 202 (66.4)
 Severe 27 (8.9)
History of amputation
 Absent 223 (73.4)
 Lesser toe(s) 29 (9.5)
 Hallux or more proximal* 52 (17.1)
 Minor lesions at entry 121 (39.8) 31 (10.2)
Plantar location of previously healed ulcer 1 (0.3)
 Non-plantar† 185 (60.9)
 Plantar 118 (38.8)
 Months since healing of previous ulcer‡ 7(2–15) 1 (0.3)
 Months duration of last two ulcers 4(2–9) 1 (0.3)
 36-Item Short Form Health Survey 13 (4.3)
 Physical functioning 59±22
 Role functioning/physical 50(0–100)
 Role functioning/emotional 100(33–100)
 Energy/fatigue 60±22
 Emotional well-being 78±18
 Social functioning 75(63–100)
 Pain 67±27
 General health 49±20
EuroQol visual analog scale 69±15 23 (7.6)
Social economic score −0.24±1.17 3 (1.0)

Data are expressed as number (%), mean±SD or median [IQR].

*Seven participants had a unilateral transtibial or transfemoral amputation.

†Including nine participants who were included based on having a history of Charcot neuro-osteoarthropathy.

‡For participants included based only on having a history of Charcot neuro-osteoarthropathy, 48 months was used.